High rate of RNAemia and impaired immunity in patients with immunodeficiency in the vaccination era

Journal of Clinical Virology, Год журнала: 2025, Номер 177, С. 105774 - 105774

Опубликована: Фев. 18, 2025

Язык: Английский

---

Current management of SARS‐CoV‐2 infection in solid organ transplant recipients: Experience derived from an ESGICH–ESOT survey

Transplant Infectious Disease, Год журнала: 2024, Номер 26(2)

Опубликована: Фев. 20, 2024

Abstract Objective Solid organ transplant (SOT) recipients have a poorer SARS‐CoV‐2 vaccine response and higher risk for COVID‐19‐associated complications. However, there is no consensus on the current management of COVID‐19 data persistent rates in SOT are lacking. Methods An electronic survey concerning was distributed among all members European Society Clinical Microbiology Infectious Diseases (ESCMID) Study Group Infections Compromised Hosts (ESGICH) Organ Transplantation (ESOT). Four major sections were covered: prevention, early COVID‐19, late COVID‐19. We developed structured questionnaire including eight multiple‐choice questions with branching logic case positive answers three open‐ended related to clinical practice. Questions asked separately lung non‐lung transplantation. Results Thirty‐two physicians from 24 different centers participated. Most ( n = 30) provided by physicians. Thirty 32 (93.75%) managed 12 (33.3%) recipients. There huge variability practice regarding treatment particularly noticeable when considering Main discordances included use nirmatrelvir alone or combination therapy immunomodulatory drugs other than steroids need treating asymptomatic viral shedding more similarity terms prophylaxis recommendations. Conclusion Despite low number respondents, this shows that many differences how experts manage infections image

Язык: Английский

---

Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up

Frontiers in Immunology, Год журнала: 2024, Номер 14

Опубликована: Янв. 4, 2024

Background Data on cellular response and the decay of antibodies T cells in time are scarce lung transplant recipients (LTRs). Additionally, development durability humoral immune responses have not been investigated patients waitlist for transplantation (WLs). Here, we report our 6-month follow-up LTRs WLs, compared with controls. Methods Humoral to two doses mRNA-1273 vaccination were assessed by determining spike (S)-specific IgG neutralizing antibodies. Cellular interferon gamma (IFN-γ) release assay (IGRA) IFN-γ ELISpot at 28 days 6 months after second vaccination. Results In LTRs, level T-cell was significantly lower Also, WLs had antibody titers Six vaccination, all groups showed a decrease responses. rate decline higher than Conclusion Our results show that if they develop, rates comparable contrast, inferior rapid both WL imply may be protected adequately vaccinations repeat boostering necessary induce protection lasts beyond immediately post-transplantation.

Язык: Английский

---

Evaluation of the effectiveness and safety of sequential vaccination with inactivated SARS‐CoV‐2 vaccine and Ad5‐nCoV booster in pediatric liver transplant recipients

Journal of Medical Virology, Год журнала: 2024, Номер 96(3)

Опубликована: Март 1, 2024

Abstract Amidst the COVID‐19 pandemic, uncertainty persists among caregivers regarding vaccination of pediatric liver transplant recipients (PLTRs). This study evaluates immunogenicity and safety in this vulnerable population. A cohort 30 PLTRs underwent sequential vaccinations with an inactivated SARS‐CoV‐2 vaccine followed by Ad5‐nCoV booster. We collected analyzed blood samples pre‐vaccination four weeks post‐vaccination to quantify antibody IGRA (IFN‐γ Release Assay) levels. also documented any adverse reactions occurring within seven days monitored participants for infections over six months post‐vaccination, culminating a comprehensive statistical analysis. The booster substantially elevated IgG (T1: 18.01, 20%; T2: 66.61, 55%) nAb 119.29, 8%; 3799.75, 80%) levels, as well T‐cell responses, comparison initial dose. first dose was associated some common reactions, such injection site pain (13.3%) fever (16.6%), but low rate systemic (16.0%). There no significant difference Omicron infection rates or RTPCR conversion times between vaccinated unvaccinated groups. Notably, following infection, individuals exhibited significantly higher titers (average IgG: 231.21 vs. 62.09 S/CO, p = 0.0003; nAb: 5246.11 2592.07 IU/mL, 0.0002). use vaccines is generally safe elicits robust humoral response, albeit limited responses.

Язык: Английский

---

Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis

Deleted Journal, Год журнала: 2024, Номер 38(2), С. 136 - 144

Опубликована: Июнь 21, 2024

Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs). This study was performed to assess the effectiveness of Tix/Cil for preexposure prophylaxis COVID-19 this population.

Язык: Английский

---

Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Март 13, 2023

Booster doses of SARS-CoV-2 vaccines improve seroconversion rates in solid organ transplant recipients (SOTRs) but the impact homologous and heterologous booster neutralizing antibody (NAb) titers their ability to interfere with variant concern Omicron are not well studied. We designed a prospective, open-label, observational clinical cohort study. 45 participants received two BNT162b2 or CoronaVac (21-day 28-day intervals, respectively) followed by first second (5-month apart each) we analyzed against SARSCoV-2 D614G (B.1 lineage) (BA.1 lineage). Our results show that SOTRs receiving an initial two-dose scheme generate lower NAbs ancestral when compared healthy controls. Although these NAb were further decreased Omicron, single both groups was sufficient increase concern. More importantly, this effect only observed those responding shots vaccination scheme. The data provided here demonstrate importance monitoring responses immunocompromised subjects planning programs risk group.

Язык: Английский

---

COVID‑19 vaccination in liver transplant recipients (Review)

Experimental and Therapeutic Medicine, Год журнала: 2023, Номер 25(6)

Опубликована: Май 3, 2023

Severe acute respiratory syndrome coronavirus 2 (Sars‑CoV‑2) infection has significantly affected immunocompromised individuals and subsequently, liver transplant recipients (LTRs). Early in the course of pandemic, this vulnerable population was prioritized for vaccination, after obtaining encouraging data about vaccination benefits on disease severity mortality. As published knowledge mainly supported from studies which were limited to healthy population, present review summarizes literature 2019 (COVID‑19) LTRs available guidelines international societies. The COVID‑19 is strongly recommended as a safe effective measure order prevent severe

Язык: Английский

---

Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Ноя. 27, 2023

Background In solid organ transplant (SOT) recipients, the humoral response following COVID-19 vaccination is reduced, as a result of their immunosuppressed treatment. this study, we investigated antibody concentrations after booster vaccinations until fifth dose, latter by monovalent or bivalent BA1 BA4/5 vaccines. addition, evaluated efficacy recording breakthrough infections, hospitalizations, and deaths. Method This prospective cohort study included 438 SOT recipients (>18 years) vaccinated with mRNA vaccines against from January 2021 March 2023. Blood samples were drawn before each tested for SARS-CoV-2 spike RBD IgG antibodies lowest highest cut-off at 7.1 5,680 BAU/mL, respectively. Vaccine information, hospitalizations collected medical records. Results Most participants received BNT162b2 61.4% five vaccine doses. The proportion in increased 86.7% fourth dose to 93.0% dose. Antibody concentration decreased 142.7 BAU/mL between third (median 132 days, Quartile 1: 123, 3: 148) 234.3 250 241, 262) among those without infection (p=0.34). When comparing Omicron BA.1 BA.4/BA.5 adapted vaccines, no significant differences found, but 20.0% receiving had compared 4.0% 7.9% who respectively (p=0.04). Since 2021, 240 (54.8%) infection, 22 hospitalized, deaths observed. Conclusions raised population. Additional doses, well led higher levels recipients. We found lower incidence infections did not wane when time doses was prolonged four eight months.

Язык: Английский

---

Booster Dose of SARS-CoV-2 mRNA Vaccine in Kidney Transplanted Patients Induces Wuhan-Hu-1 Specific Neutralizing Antibodies and T Cell Activation but Lower Response against Omicron Variant

Viruses, Год журнала: 2023, Номер 15(5), С. 1132 - 1132

Опубликована: Май 9, 2023

Kidney transplanted recipients (KTR) are at high risk of severe SARS-CoV-2 infection due to immunosuppressive therapy. Although several studies reported antibody production in KTR after vaccination, data related immunity the Omicron (B.1.1.529) variant sparse. Herein, we analyzed anti-SARS-CoV-2 immune response seven and eight healthy controls second third dose mRNA vaccine (BNT162b2). A significant increase neutralizing (nAb) titers were detected against pseudoviruses expressing Wuhan-Hu-1 spike (S) protein both groups, although nAbs lower than controls. S low with no 3rd KTR. Reactivity CD4+ T cells boosting was observed when challenged peptides, while peptides less effective groups. IFN-γ ancestral confirming antigen-specific cell activation. Our study demonstrates that induces KTR, an increment humoral immunity. Instead, cellular immunogenic vaccinated subjects.

Язык: Английский

---

Clinical characteristics and outcomes of liver transplant recipients infected by Omicron during the opening up of the dynamic zero-coronavirus disease policy in China: A prospective, observational study

American Journal of Transplantation, Год журнала: 2023, Номер 24(4), С. 631 - 640

Опубликована: Окт. 18, 2023

We analyzed the characteristics, risk factors, outcomes, and post-coronavirus disease 2019 (COVID-19) symptoms in liver transplant recipients China's late 2022 COVID-19 wave. Recipients with were enrolled from December 1, 2022, to January 31, 2023, followed up until May 2023. Baseline characteristic data collected. A total of 930 included, a vaccination rate (non-mRNA) 40.0%. Among 726 (78.1%) COVID-19, 641 (88.3%) patients treated at home, 81 (11.2%) required hospitalization general wards, 4 (0.6%) intensive care, 1 (0.1%) patient died because COVID-19. Severe acute respiratory syndrome coronavirus 2 infection was related close contact confirmed cases (P < .001) condition end-stage kidney .046). Older age, male sex, less vaccination, hypertension independent factors for hospitalization. Fatigue (36.9%) most common symptom post-COVID-19, by memory loss (35.7%) sleep disturbance (23.9%). Two doses vaccines had protective effect against these post-COVID-19 .05). During this Omicron outbreak, susceptible frequent but low mortality. non-mRNA could protect recipient symptoms.

Язык: Английский

---